TRAW has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TRAW has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-28), Traws Pharma's current share price is $0.6207. Traws Pharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $201.19. Traws Pharma's Cyclically Adjusted PS Ratio for today is 0.00.
The historical rank and industry rank for Traws Pharma's Cyclically Adjusted PS Ratio or its related term are showing as below:
During the past years, Traws Pharma's highest Cyclically Adjusted PS Ratio was 0.01. The lowest was 0.01. And the median was 0.01.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Traws Pharma's adjusted revenue per share data for the three months ended in Dec. 2023 was $0.003. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $201.19 for the trailing ten years ended in Dec. 2023.
The historical data trend for Traws Pharma's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Traws Pharma Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Traws Pharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Traws Pharma's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Traws Pharma's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Traws Pharma's Cyclically Adjusted PS Ratio for today is calculated as
Cyclically Adjusted PS Ratio | = | Share Price | / | Cyclically Adjusted Revenue per Share |
= | 0.6207 | / | 201.19 | |
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Traws Pharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:
For example, Traws Pharma's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Dec. 2023 (Change) | * | Current CPI (Dec. 2023) |
= | 0.003 | / | 129.4194 | * | 129.4194 | |
= | 0.003 |
Current CPI (Dec. 2023) = 129.4194.
Traws Pharma Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201403 | 44.700 | 99.695 | 58.028 |
201406 | 12.500 | 100.560 | 16.087 |
201409 | 11.400 | 100.428 | 14.691 |
201412 | 11.400 | 99.070 | 14.892 |
201503 | 11.400 | 99.621 | 14.810 |
201506 | 12.300 | 100.684 | 15.810 |
201509 | 162.200 | 100.392 | 209.100 |
201512 | 872.455 | 99.792 | 1,131.475 |
201603 | 122.833 | 100.470 | 158.225 |
201606 | 187.333 | 101.688 | 238.420 |
201609 | 68.792 | 101.861 | 87.404 |
201612 | 5.767 | 101.863 | 7.327 |
201703 | 7.000 | 102.862 | 8.807 |
201706 | 8.100 | 103.349 | 10.143 |
201709 | 2.500 | 104.136 | 3.107 |
201712 | 3.109 | 104.011 | 3.868 |
201803 | 8.418 | 105.290 | 10.347 |
201806 | 1.790 | 106.317 | 2.179 |
201809 | 0.317 | 106.507 | 0.385 |
201812 | 0.156 | 105.998 | 0.190 |
201903 | 0.173 | 107.251 | 0.209 |
201906 | 5.093 | 108.070 | 6.099 |
201909 | 0.154 | 108.329 | 0.184 |
201912 | 0.004 | 108.420 | 0.005 |
202003 | 0.005 | 108.902 | 0.006 |
202006 | 0.005 | 108.767 | 0.006 |
202009 | 0.005 | 109.815 | 0.006 |
202012 | 0.005 | 109.897 | 0.006 |
202103 | 0.004 | 111.754 | 0.005 |
202106 | 0.004 | 114.631 | 0.005 |
202109 | 0.004 | 115.734 | 0.004 |
202112 | 0.003 | 117.630 | 0.003 |
202203 | 0.003 | 121.301 | 0.003 |
202206 | 0.003 | 125.017 | 0.003 |
202209 | 0.003 | 125.227 | 0.003 |
202212 | 0.003 | 125.222 | 0.003 |
202303 | 0.003 | 127.348 | 0.003 |
202306 | 0.003 | 128.729 | 0.003 |
202309 | 0.003 | 129.860 | 0.003 |
202312 | 0.003 | 129.419 | 0.003 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Thank you for viewing the detailed overview of Traws Pharma's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Victor M Moyo | officer: CHIEF MEDICAL OFFICER | 12 PENNS TRAIL, NEWTOWN PA 18940 |
Trafford Clarke | director | 12 PENNS TRAIL, NEWTOWN PA 18940 |
Peter Atadja | director | 12 PENNS TRAIL, NEWTOWN PA 18940 |
Abraham N. Oler | officer: VP Corp Dev & Gen Counsel | C/O SPECTRUM PHARMACEUTICALS, 11500 SOUTH EASTERN AVENUE, SUITE 240, HENDERSON NV 89052 |
Steven M Fruchtman | officer: Chief Medical Officer | 375 PHEASANT RUN, NEWTOWN PA 18940 |
James J Marino | director | C/O ONCONOVA THERAPEUTICS, 375 PHEASANT RUN, NEWTOWN PA 18940 |
Gelder Mark S. Md | officer: Chief Medical Officer | C/O A.P. PHARMA, INC., 123 SAGINAW DRIVE, REDWOOD CITY CA 94063 |
Mark Patrick Guerin | officer: Chief Accounting Officer | 375 PHEASANT RUN, NEWTOWN PA 18940 |
Mary Teresa Shoemaker | director | 375 PHEASANT RUN, NEWTOWN PA 18940 |
Michael B Hoffman | director | 1 GREENWICH OFFICE PARK, GREENWICH CT 06831 |
E Premkumar Reddy | director | 375 PHEASANT RUN, NEWTOWN PA 18940 |
Jerome Groopman | director | C/O GENTA INC, TWO CONNELL DR, BERKELEY HEIGHTS NJ 07922 |
Viren Mehta | director | OSI PHARMACEUTICALS INC, 58 S SERVICE RD STE 110, MELVILLE NY 11747 |
Tyndall Capital Partners L P | 10 percent owner | 150 EAST 58TH STREET, 14TH FLOOR, NEW YORK NY 10155 |
Armistice Capital, Llc | 10 percent owner | 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
From GuruFocus
By GuruFocus Research • 02-29-2024
By GuruFocus Research • 02-29-2024
By GuruFocus Research • 02-29-2024
By GuruFocus Research • 02-29-2024
By GuruFocus Research • 02-29-2024
By GuruFocus Research • 02-29-2024
By GuruFocus Research • 02-29-2024
By GuruFocus Research • 02-29-2024
By GuruFocus Research • 02-29-2024
By GuruFocus Research • 02-29-2024